Non-Small Cell Lung Cancer with Malignant Pleural Effusion May Require Primary Tumor Radiotherapy in Addition to Drug Treatment

References

• Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85(1). doi:10.5334/aogh.2419
   PubMed Web of Science ®Google Scholar
• Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology. 2015;20(4):654–659. doi:10.1111/resp.12496
   PubMed Web of Science ®Google Scholar
• Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098–1104. doi:10.1136/thoraxjnl-2014-205285
   PubMed Web of Science ®Google Scholar
• Bibby AC, Clive AO, Slade GC, et al. Survival in patients with malignant pleural effusions who developed pleural infection: a retrospective case review from six UK centers. Chest. 2015;148(1):235–241. doi:10.1378/chest.14-2199
   PubMed Web of Science ®Google Scholar
• Terra RM, Dela Vega A. Treatment of malignant pleural effusion. J Vis Surg. 2018;4:110. doi:10.21037/jovs.2018.05.02
   PubMedGoogle Scholar
• Ryu JS, Ryu HJ, Lee SN, et al. Prognostic impact of minimal pleural effusion in non-small-cell lung cancer. J Clin Oncol. 2014;32(9):960–967. doi:10.1200/JCO.2013.50.5453
   PubMed Web of Science ®Google Scholar
• Penz E, Watt KN, Hergott CA, Rahman NM, Psallidas I. Management of malignant pleural effusion: challenges and solutions. Cancer Manag Res. 2017;50:229–241. doi:10.2147/CMAR.S95663
   Web of Science ®Google Scholar
• Postmus PE, Brambilla E, Chansky K, et al. The IASLC lung cancer staging project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol. 2007;2(8):686–693.
   PubMed Web of Science ®Google Scholar
• Eberhardt WE, Mitchell A, Crowley J, et al. The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2015;10(11):1515–1522. doi:10.1097/JTO.0000000000000673
   PubMed Web of Science ®Google Scholar
• Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer. 2013;82(2):197–203. doi:10.1016/j.lungcan.2013.07.026
   PubMed Web of Science ®Google Scholar
• Koshy M, Malik R, Mahmood U, Rusthoven CG, Sher DJ. Comparative effectiveness of aggressive thoracic radiation therapy and concurrent chemoradiation therapy in metastatic lung cancer. Pract Radiat Oncol. 2015;5(6):374–382. doi:10.1016/j.prro.2015.07.009
   PubMedGoogle Scholar
• Lopez Guerra JL, Gomez D, Zhuang Y, et al. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys. 2012;84(1):e61–67. doi:10.1016/j.ijrobp.2012.02.054
   PubMed Web of Science ®Google Scholar
• Su S, Li T, Lu B, et al. Three-dimensional radiation therapy to the primary tumor with concurrent chemotherapy in patients with stage IV non-small cell lung cancer: results of a multicenter phase 2 study from PPRA-RTOG, China. Int J Radiat Oncol Biol Phys. 2015;93(4):769–777. doi:10.1016/j.ijrobp.2015.08.012
   PubMed Web of Science ®Google Scholar
• Arrieta O, Barrón F, Maldonado F, et al. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: a Phase II study. Lung Cancer. 2019;130:67–75. doi:10.1016/j.lungcan.2019.02.006
   PubMed Web of Science ®Google Scholar
• Zheng L, Wang Y, Xu Z, et al. Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations. Oncologist. 2019;24:1031–e612. doi:10.1634/theoncologist.2019-0285
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ichinose Y, Shimamatsu S, et al. Preoperative concurrent chemoradiotherapy followed by extrapleural pneumonectomy for patients with non-small cell lung cancer with malignant pleural effusion and/or pleural nodules: ten-year results of a prematurely terminated single institute phase II trial. Surg Oncol. 2015;24(2):78–83. doi:10.1016/j.suronc.2015.02.004
   PubMed Web of Science ®Google Scholar
• Ried M, Hofmann HS. The treatment of pleural carcinosis with malignant pleural effusion. Dtsch Arztebl Int. 2013;110(18):313–318. doi:10.3238/arztebl.2013.0313
   PubMed Web of Science ®Google Scholar
• Higginson DS, Chen RC, Tracton G, et al. The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2012;84(3):e385–392. doi:10.1016/j.ijrobp.2012.04.045
   PubMed Web of Science ®Google Scholar
• Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol. 2009;48(4):578–583. doi:10.1080/02841860802662722
   PubMed Web of Science ®Google Scholar
• Patel SH, Rimner A, Foster A, et al. Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. Lung Cancer. 2017;108:109–114. doi:10.1016/j.lungcan.2017.03.010
   PubMed Web of Science ®Google Scholar
• Petrelli F, Ghidini A, Cabiddu M, et al. Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: a systematic review and meta-analysis. Lung Cancer. 2018;126:194–200. doi:10.1016/j.lungcan.2018.11.017
   PubMed Web of Science ®Google Scholar
• Rodrigues G, Videtic GM, Sur R, et al. Palliative thoracic radiotherapy in lung cancer: an American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2011;1(2):60–71. doi:10.1016/j.prro.2011.01.005
   PubMedGoogle Scholar
• Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27(2):131–146. doi:10.3109/02841868809090333
   PubMed Web of Science ®Google Scholar
• Wang Y, Shi XH, He SQ, et al. Comparison between continuous accelerated hyperfractionated and late-course accelerated hyperfractionated radiotherapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2002;54(1):131–136. doi:10.1016/S0360-3016(02)02892-4
   PubMed Web of Science ®Google Scholar
• Liu CX, Li XY, Gao XS. Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma. Chin J Cancer. 2010;29(10):889–899. doi:10.5732/cjc.010.10147
   PubMedGoogle Scholar
• Wang D, Li B, Wang Z, et al. Functional dose-volume histograms for predicting radiation pneumonitis in locally advanced non-small cell lung cancer treated with late-course accelerated hyperfractionated radiotherapy. Exp Ther Med. 2011;2(5):1017–1022. doi:10.3892/etm.2011.301
   PubMed Web of Science ®Google Scholar
• Chen M, Chen YY, Bao Y, et al. Neoadjuvant chemotherapy followed by late-course accelerated hyperfractionated radiation therapy for locally advanced non-small-cell lung cancer: long-term results of a phase I/II clinical trial. Clin Lung Cancer. 2005;6(5):304–309. doi:10.3816/CLC.2005.n.010
   PubMedGoogle Scholar
• Su S, Hu Y, Ouyang W, et al. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: secondary analysis of two prospective studies. BMC Cancer. 2016;16(1):908. doi:10.1186/s12885-016-2952-3
   PubMed Web of Science ®Google Scholar
• Yang J, Lee OJ, Son SM, et al. EGFR mutation status in lung adenocarcinoma-associated malignant pleural effusion and efficacy of EGFR tyrosine kinase inhibitors. Cancer Res Treat. 2018;50(3):908–916. doi:10.4143/crt.2017.378
   PubMed Web of Science ®Google Scholar
• Wu SG, Yu CJ, Tsai MF, et al. Survival of lung adenocarcinoma patients with malignant pleural effusion. Eur Respir J. 2013;41(6):1409–1418. doi:10.1183/09031936.00069812
   PubMed Web of Science ®Google Scholar
• Tao H, Meng Q, Li M, Shi L, Tang J, Liu Z. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion. Thorac Cancer. 2018;9(2):298–304. doi:10.1111/1759-7714.12582
   PubMed Web of Science ®Google Scholar
• Usui K, Sugawara S, Nishitsuji M, et al. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. Lung Cancer. 2016;99:131–136. doi:10.1016/j.lungcan.2016.07.003
   PubMed Web of Science ®Google Scholar
• Feng X, Zhu L, Xiong X, et al. Therapeutical effect of intrapleural perfusion with hyperthermic chemotherapy on malignant pleural effusion under video-assisted thoracoscopic surgery. Int J Hyperthermia. 2018;34(4):479–485. doi:10.1080/02656736.2017.1340676
   PubMed Web of Science ®Google Scholar
• Arrieta O, Villarreal-Garza C, Zamora J, et al. Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation. Radiat Oncol. 2011;6:166. doi:10.1186/1748-717X-6-166
   PubMed Web of Science ®Google Scholar
• Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 2008;27(12):2037–2049. doi:10.1002/sim.3150
   PubMed Web of Science ®Google Scholar
• Austin PC. Type I error rates, coverage of confidence intervals, and variance estimation in propensity-score matched analyses. Int J Biostat. 2009;5(1):Article13. doi:10.2202/1557-4679.1146
   Google Scholar
• Newgard CD, Hedges JR, Arthur M, Mullins RJ. Advanced statistics: the propensity score--a method for estimating treatment effect in observational research. Acad Emerg Med. 2004;11(9):953–961. doi:10.1197/j.aem.2004.02.530
   PubMed Web of Science ®Google Scholar
• Fairchild A, Harris K, Barnes E, et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol. 2008;26(24):4001–4011. doi:10.1200/JCO.2007.15.3312
   PubMed Web of Science ®Google Scholar
• Wang J, Ji Z, Wang X, et al. Radical thoracic radiotherapy may provide favorable outcomes for stage IV non-small cell lung cancer. Thorac Cancer. 2016;7(2):182–189. doi:10.1111/1759-7714.12305
   PubMed Web of Science ®Google Scholar
• Su S, Hu Y, Ouyang W, et al. The survival outcomes and prognosis of stage IV non-small-cell lung cancer treated with thoracic three-dimensional radiotherapy combined with chemotherapy. Radiat Oncol. 2014;9:290. doi:10.1186/s13014-014-0290-7
   PubMed Web of Science ®Google Scholar
• Tanaka T, Matsuoka M, Sutani A, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer. 2010;126(3):651–655. doi:10.1002/ijc.24746
   PubMed Web of Science ®Google Scholar
• Yatabe Y, Kerr KM, Utomo A, et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J Thorac Oncol. 2015;10(3):438–445. doi:10.1097/JTO.0000000000000422
   PubMed Web of Science ®Google Scholar
• Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–2190. doi:10.1200/JCO.2009.26.2543
   PubMed Web of Science ®Google Scholar
• Curran WJ, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized Phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452–1460. doi:10.1093/jnci/djr325
   PubMedGoogle Scholar
• Zhang Q, Cai XW, Zhu ZF, et al. Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer. Anticancer Drugs. 2015;26(4):456–463. doi:10.1097/CAD.0000000000000215
   PubMed Web of Science ®Google Scholar